Head-to-head evidence
HRS-1301 vs Ongericimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline
HRS-1301
Developed by Jiangsu Hengrui Pharmaceuticals and partners
NCT06857253 · Phase 1 · completed
This is a real randomized, blinded, placebo-controlled study, which is a solid design, but its primary measure is adverse-event safety monitoring rather than a cholesterol or cardiovascular outcome, and results have not been posted yet.
Ongericimab · Junshida
Developed by Shanghai Junshi Bioscience
NCT04781114 · Phase 3 · completed
This large, randomized, placebo-controlled trial kept participants, care providers, investigators and outcome assessors blind to treatment assignment. Its primary endpoint was clearly met: both ongericimab dose regimens produced large, statistically significant reductions in LDL cholesterol versus placebo.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HRS-1301's landscape · Ongericimab's landscape